Literature DB >> 31978385

TGR5 promotes cholangiocarcinoma by interacting with mortalin.

Ai-Di Li1, Xiao-Li Xie1, Wei Qi1, Wen-Bin Wang2, Jun-Ji Ma1, Dong-Qiang Zhao1, Xiao-Yu Jiang1, Lei Chen1, Yun Bai3, Hui-Qing Jiang4.   

Abstract

Takeda-G-protein-receptor-5 (TGR5) is a G-protein-coupled receptor (GPCR) activated by bile acids, and mortalin is a multipotent chaperone of the HSP70 family. In the present study, TGR5 was detected by immunohistochemistry (IHC) in extrahepatic cholangiocarcinoma (ECC) specimens, and TGR5 expression in ECC tissues and adjacent tissues was compared. In vitro TGR5 was overexpressed and knocked down in human intrahepatic cholangiocarcinoma (ICC) cell line RBE and human extrahepatic cholangiocarcinoma (ECC) cell line QBC-939 to observe its effects on the biological behavior of cholangiocarcinoma (CC) cells, including proliferation, apoptosis and migration. In vivo xenograft model was constructed to explore the role of TGR5 in CC growth. Proteins that interacted with TGR5 were screened using an immunoprecipitation spectrometry approach, and the identified protein was down-regulated to investigate its contribution to CC growth. The present study demonstrated that TGR5 is highly expressed in CC tissues, and strong TGR5 expression may indicate high malignancy in CC. Furthermore, TGR5 promotes CC cell proliferation, migration, and apoptosis resistance. TGR5 boosts CC growth in vivo. In addition, TGR5 combines with mortalin and regulates mortalin expression in the CC cell line. Mortalin participates in the TGR5-induced increase in CC cell proliferation. In conclusion, TGR5 is of clinical significance based on its implications for the degree of malignancy in patients with CC. Mortalin may be a downstream component regulated by TGR5, and TGR5 promotes cholangiocarcinoma at least partially by interacting with mortalin and upregulating its expression. Both TGR5 and mortalin are positive regulators, and may serve as potential therapeutic targets for CC.
Copyright © 2020. Published by Elsevier Inc.

Entities:  

Keywords:  Cholangiocarcinoma; Mortalin; Proliferation; TGR5

Year:  2020        PMID: 31978385     DOI: 10.1016/j.yexcr.2020.111855

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  6 in total

1.  Investigation of the potential role of TGR5 in pancreatic cancer by a comprehensive molecular experiments and the liquid chromatography mass spectrometry (LC-MS) based metabolomics.

Authors:  Yangyang Lei; Guoping Li; Jianke Li; Shanshan Gao; Ming Lei; Gaoquan Gong; Changyu Li; Yi Chen; Chenggang Wang; Xiaolin Wang
Journal:  Discov Oncol       Date:  2022-06-11

Review 2.  Bile acids and their receptors: modulators and therapeutic targets in liver inflammation.

Authors:  Anna Bertolini; Romina Fiorotto; Mario Strazzabosco
Journal:  Semin Immunopathol       Date:  2022-04-12       Impact factor: 11.759

Review 3.  Therapeutic Opportunities of GPBAR1 in Cholestatic Diseases.

Authors:  Fangling Zhang; Xiaolin Xiao; Yong Li; Hefei Wu; Xinyu Deng; Yinxiao Jiang; Wenwen Zhang; Jian Wang; Xiao Ma; Yanling Zhao
Journal:  Front Pharmacol       Date:  2022-01-13       Impact factor: 5.810

4.  TGR5 deficiency activates antitumor immunity in non-small cell lung cancer via restraining M2 macrophage polarization.

Authors:  Lifang Zhao; Hongyan Zhang; Xueqing Liu; Shan Xue; Dongfang Chen; Jing Zou; Handong Jiang
Journal:  Acta Pharm Sin B       Date:  2021-07-21       Impact factor: 11.413

Review 5.  Review article: therapeutic aspects of bile acid signalling in the gut-liver axis.

Authors:  Benedikt Simbrunner; Michael Trauner; Thomas Reiberger
Journal:  Aliment Pharmacol Ther       Date:  2021-09-23       Impact factor: 9.524

Review 6.  Cyclic AMP Signaling in Biliary Proliferation: A Possible Target for Cholangiocarcinoma Treatment?

Authors:  Leonardo Baiocchi; Ilaria Lenci; Martina Milana; Lindsey Kennedy; Keisaku Sato; Wenjun Zhang; Burcin Ekser; Ludovica Ceci; Vik Meadows; Shannon Glaser; Gianfranco Alpini; Heather Francis
Journal:  Cells       Date:  2021-07-04       Impact factor: 6.600

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.